JP2011190259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011190259A5 JP2011190259A5 JP2011052316A JP2011052316A JP2011190259A5 JP 2011190259 A5 JP2011190259 A5 JP 2011190259A5 JP 2011052316 A JP2011052316 A JP 2011052316A JP 2011052316 A JP2011052316 A JP 2011052316A JP 2011190259 A5 JP2011190259 A5 JP 2011190259A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- acceptable excipient
- disintegrant
- methylnaltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31301810P | 2010-03-11 | 2010-03-11 | |
| US61/313,018 | 2010-03-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178184A Division JP2016029054A (ja) | 2010-03-11 | 2015-09-10 | メチルナルトレキソンの経口製剤および親油性塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011190259A JP2011190259A (ja) | 2011-09-29 |
| JP2011190259A5 true JP2011190259A5 (enExample) | 2013-12-12 |
| JP6143409B2 JP6143409B2 (ja) | 2017-06-07 |
Family
ID=44148539
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011052316A Active JP6143409B2 (ja) | 2010-03-11 | 2011-03-10 | メチルナルトレキソンの経口製剤および親油性塩 |
| JP2015178184A Pending JP2016029054A (ja) | 2010-03-11 | 2015-09-10 | メチルナルトレキソンの経口製剤および親油性塩 |
| JP2017152275A Active JP6429955B2 (ja) | 2010-03-11 | 2017-08-07 | メチルナルトレキソンの経口製剤および親油性塩 |
| JP2018203748A Active JP6647368B2 (ja) | 2010-03-11 | 2018-10-30 | メチルナルトレキソンの経口製剤および親油性塩 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178184A Pending JP2016029054A (ja) | 2010-03-11 | 2015-09-10 | メチルナルトレキソンの経口製剤および親油性塩 |
| JP2017152275A Active JP6429955B2 (ja) | 2010-03-11 | 2017-08-07 | メチルナルトレキソンの経口製剤および親油性塩 |
| JP2018203748A Active JP6647368B2 (ja) | 2010-03-11 | 2018-10-30 | メチルナルトレキソンの経口製剤および親油性塩 |
Country Status (32)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1615646B2 (en) | 2003-04-08 | 2022-07-27 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| CA2682129A1 (en) | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
| US9061076B2 (en) | 2007-05-25 | 2015-06-23 | North Carolina State University | Viral nanoparticle cell-targeted delivery platform |
| SG10201501821RA (en) | 2010-03-11 | 2015-05-28 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| WO2013096444A1 (en) * | 2011-12-19 | 2013-06-27 | Salix Pharmaceuticals, Ltd. | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
| WO2015191686A1 (en) * | 2014-06-10 | 2015-12-17 | Salix Pharmaceuticals, Inc. | Methods of administering methylnaltrexone |
| CA2954370A1 (en) * | 2014-07-08 | 2016-01-14 | Insys Pharma, Inc. | Sublingual naloxone spray |
| US10722510B2 (en) * | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US10441538B2 (en) * | 2014-07-08 | 2019-10-15 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US10617686B2 (en) * | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| WO2016061531A1 (en) | 2014-10-17 | 2016-04-21 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
| WO2020128583A1 (en) * | 2018-12-19 | 2020-06-25 | Friulchem S.P.A. | Process for the manufacture of a tablet of rifaximin and tablet of rifaximin |
| AU2020268767B8 (en) * | 2019-05-07 | 2025-08-07 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
| WO2020245214A1 (en) | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
| CA3177250A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
| WO2023031955A1 (en) * | 2021-08-28 | 2023-03-09 | Redasani Vijayendrakumar Virendrakumar Ji | Oral pharmaceutical compositions of methylnaltrexone and salt thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
| CA1297218C (en) | 1986-03-14 | 1992-03-10 | Edward David Weil | Thermally stable diphosphonate-type flame retardant additive for plastics |
| US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
| US5780012A (en) | 1990-06-21 | 1998-07-14 | Huland; Edith | Method for reducing lung afflictions by inhalation of cytokine solutions |
| WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5866154A (en) | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| HU224964B1 (en) | 1997-02-14 | 2006-04-28 | Goedecke Ag | Process for stabilization of naloxone and stable pharmaceutical compositions containing naloxone |
| US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
| US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
| US6559158B1 (en) | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
| ATE210983T1 (de) | 1997-11-03 | 2002-01-15 | Stada Arzneimittel Ag | Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum |
| US20030158220A1 (en) | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| GB0100115D0 (en) | 2001-01-04 | 2001-02-14 | Alchemia Pty Ltd | Delivery systems |
| CN1525851A (zh) * | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| CA2449175A1 (en) | 2001-06-05 | 2002-12-12 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
| DK2939696T3 (en) | 2001-10-18 | 2016-05-23 | Nektar Therapeutics | Polymer Conjugates of Opioid Antagonists |
| CA2468525A1 (en) * | 2001-11-29 | 2003-06-12 | Schering Corporation | Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl] |
| EP2289492B1 (en) | 2002-03-14 | 2016-12-07 | Euro-Celtique S.A. | Naltrexone hydrochloride compositions |
| US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
| CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| CA2521369A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| EP1615646B2 (en) | 2003-04-08 | 2022-07-27 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
| ES2625343T3 (es) * | 2003-07-15 | 2017-07-19 | Evonik Corporation | Método para la preparación de formulaciones de liberación controlada |
| US8946262B2 (en) | 2003-12-04 | 2015-02-03 | Adolor Corporation | Methods of preventing and treating gastrointestinal dysfunction |
| ATE516011T1 (de) | 2003-12-19 | 2011-07-15 | Schering Corp | Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten |
| ATE500819T1 (de) * | 2003-12-31 | 2011-03-15 | Bend Res Inc | Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren |
| CN1294728C (zh) | 2004-08-05 | 2007-01-10 | 华为技术有限公司 | 边缘路由器提供服务质量保证的方法及系统 |
| WO2006039705A2 (en) | 2004-09-30 | 2006-04-13 | Becton, Dickinson And Company | Method for reducing or eliminating residue in a glass medical container and container made in accordance therewith |
| US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
| AR057035A1 (es) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2008021394A2 (en) * | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
| JP4970542B2 (ja) * | 2006-08-16 | 2012-07-11 | ノバルティス アーゲー | 有色レンズケア溶液の時間的光漂白及びその使用 |
| JP2010506833A (ja) * | 2006-10-11 | 2010-03-04 | アルファーマ，インコーポレイテッド | 医薬組成物 |
| TW200843802A (en) | 2007-02-09 | 2008-11-16 | Drugtech Corp | Compositions for improving gastrointestinal nutrient and drug absorption |
| JP5469593B2 (ja) * | 2007-03-29 | 2014-04-16 | ワイス・エルエルシー | 末梢性オピオイド受容体アンタゴニストおよびその使用 |
| CA2682129A1 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
| JP5178064B2 (ja) * | 2007-06-27 | 2013-04-10 | 富士フイルム株式会社 | 金属表面粗化層を有する金属層積層体及びその製造方法 |
| EA201001643A1 (ru) * | 2008-05-07 | 2011-06-30 | Нектар Терапеутикс | Пероральное введение периферически действующих опиоидных антагонистов |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| JP5525247B2 (ja) * | 2009-08-04 | 2014-06-18 | 株式会社神戸製鋼所 | 高強度で曲げ加工性に優れた銅合金 |
| SG10201501821RA (en) | 2010-03-11 | 2015-05-28 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
| TW201235609A (en) * | 2010-07-13 | 2012-09-01 | Koninkl Philips Electronics Nv | Low cost mounting of LEDs in TL-retrofit tubes |
-
2011
- 2011-03-10 SG SG10201501821RA patent/SG10201501821RA/en unknown
- 2011-03-10 MA MA35290A patent/MA34146B1/fr unknown
- 2011-03-10 UA UAA201602306A patent/UA123856C2/uk unknown
- 2011-03-10 CA CA2789798A patent/CA2789798C/en active Active
- 2011-03-10 US US13/045,108 patent/US8524276B2/en active Active
- 2011-03-10 KR KR1020187030676A patent/KR101982482B1/ko active Active
- 2011-03-10 WO PCT/US2011/027913 patent/WO2011112816A1/en not_active Ceased
- 2011-03-10 AU AU2011224275A patent/AU2011224275B2/en active Active
- 2011-03-10 NZ NZ601595A patent/NZ601595A/en unknown
- 2011-03-10 TW TW105105359A patent/TWI605814B/zh active
- 2011-03-10 BR BR112012022873-0A patent/BR112012022873B1/pt active IP Right Grant
- 2011-03-10 CN CN201180013511.1A patent/CN102918039B/zh active Active
- 2011-03-10 SG SG10201606618PA patent/SG10201606618PA/en unknown
- 2011-03-10 MY MYPI2012003442A patent/MY160727A/en unknown
- 2011-03-10 EA EA201270741A patent/EA029096B1/ru unknown
- 2011-03-10 GE GEAP201112868A patent/GEP201606550B/en unknown
- 2011-03-10 AR ARP110100757A patent/AR080491A1/es unknown
- 2011-03-10 MX MX2015010803A patent/MX368805B/es unknown
- 2011-03-10 CN CN201710321015.1A patent/CN107308125B/zh active Active
- 2011-03-10 KR KR1020127026488A patent/KR101913102B1/ko active Active
- 2011-03-10 TW TW100108143A patent/TWI589293B/zh active
- 2011-03-10 JP JP2011052316A patent/JP6143409B2/ja active Active
- 2011-03-10 PH PH1/2012/501622A patent/PH12012501622A1/en unknown
- 2011-03-10 PE PE2012001538A patent/PE20130063A1/es active IP Right Grant
- 2011-03-10 NZ NZ703564A patent/NZ703564A/en unknown
- 2011-03-10 SG SG2012057261A patent/SG183133A1/en unknown
- 2011-03-10 NZ NZ702826A patent/NZ702826A/en unknown
- 2011-03-10 MX MX2012009125A patent/MX349145B/es active IP Right Grant
- 2011-03-11 PL PL11157837T patent/PL2371357T3/pl unknown
- 2011-03-11 PL PL17153285T patent/PL3178472T3/pl unknown
- 2011-03-11 ES ES11157837.3T patent/ES2623926T3/es active Active
- 2011-03-11 HU HUE11157837A patent/HUE033133T2/en unknown
- 2011-03-11 EP EP17153285.6A patent/EP3178472B1/en active Active
- 2011-03-11 EP EP11157837.3A patent/EP2371357B1/en active Active
- 2011-10-03 UA UAA201211733A patent/UA111717C2/uk unknown
-
2012
- 2012-08-02 TN TNP2012000392A patent/TN2012000392A1/en unknown
- 2012-08-07 CL CL2012002192A patent/CL2012002192A1/es unknown
- 2012-08-14 IL IL221452A patent/IL221452A/en active IP Right Grant
- 2012-08-23 GT GT201200247A patent/GT201200247A/es unknown
- 2012-09-19 CR CR20120476A patent/CR20120476A/es unknown
- 2012-10-02 EC ECSP12012208 patent/ECSP12012208A/es unknown
- 2012-10-10 CO CO12178897A patent/CO6630134A2/es unknown
-
2013
- 2013-07-31 US US13/956,050 patent/US9314461B2/en active Active
- 2013-08-14 US US13/966,779 patent/US8956651B2/en active Active
-
2015
- 2015-09-10 JP JP2015178184A patent/JP2016029054A/ja active Pending
-
2016
- 2016-03-15 US US15/070,555 patent/US20160206612A1/en not_active Abandoned
-
2017
- 2017-08-07 JP JP2017152275A patent/JP6429955B2/ja active Active
-
2018
- 2018-10-30 JP JP2018203748A patent/JP6647368B2/ja active Active
- 2018-12-13 US US16/219,159 patent/US10376505B2/en active Active
- 2018-12-13 US US16/219,681 patent/US10307417B2/en active Active
- 2018-12-18 ZA ZA2018/08498A patent/ZA201808498B/en unknown
-
2019
- 2019-06-24 US US16/450,157 patent/US10507206B2/en active Active
- 2019-10-25 US US16/664,239 patent/US20200121673A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011190259A5 (enExample) | ||
| JP6647368B2 (ja) | メチルナルトレキソンの経口製剤および親油性塩 | |
| JP2008535867A5 (enExample) | ||
| CZ413497A3 (cs) | Formulace s řízeným uvolňováním u špatně rozpustného léčiva | |
| JP2008524332A (ja) | 睡眠傷害のための医薬組成物 | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| JP2007509055A (ja) | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の経口投与 | |
| JP7374885B2 (ja) | 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤 | |
| JP2006527256A5 (enExample) | ||
| RU2017143849A (ru) | Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения | |
| WO2019036712A1 (en) | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME OR ADENOMYOSIS | |
| BR112014009506B1 (pt) | preparação estabilizada de liberação sustentada contendo eperisona | |
| EP2956123A1 (en) | Solid pharmaceutical dosage form of dolutegravir | |
| AU2005204014B2 (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent | |
| US20170319519A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| JP2015501849A5 (enExample) | ||
| US20110319464A1 (en) | Methods for treating benign prostatic hyperplasia | |
| WO2013006146A1 (en) | Effervescent formulations comprising dexketoprofen | |
| WO1999065475A2 (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| ES2897576T3 (es) | Composiciones antimicrobianas con agentes efervescentes | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| WO2013180675A1 (en) | Tablet formulation comprising dapoxetine | |
| KR20250156840A (ko) | 경구 생체이용률을 개선하기 위한 약학적 조성물 | |
| WO2021236891A1 (en) | Gut-targeted phosphodiesterase inhibitors | |
| WO2009025571A1 (en) | Sublingual or buccal pharmaceutical compositions comprising succinic acid for treating alzheimer's disease |